Windle Wealth LLC Purchases New Position in Johnson & Johnson (NYSE:JNJ)

Windle Wealth LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 33,227 shares of the company’s stock, valued at approximately $5,869,000. Johnson & Johnson makes up about 4.6% of Windle Wealth LLC’s holdings, making the stock its 9th biggest position.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares in the last quarter. State Street Corp grew its stake in shares of Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Johnson & Johnson by 3.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Johnson & Johnson by 2.7% during the 3rd quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock worth $1,919,726,000 after buying an additional 310,473 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Atlantic Securities dropped their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Morgan Stanley boosted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Raymond James dropped their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Piper Sandler dropped their price objective on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Price Performance

Shares of JNJ opened at $160.99 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a 50 day simple moving average of $158.97 and a 200 day simple moving average of $166.83. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The firm has a market capitalization of $418.37 billion, a PE ratio of 33.68, a P/E/G ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same period in the previous year, the firm earned $2.67 EPS. Johnson & Johnson’s quarterly revenue was up 5.6% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s payout ratio is currently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.